Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis

Cancer Science

Volumn 105, Issue 10, 2014, Pages 1254-1260

  Takaki, Yoko ^a   Saito, Yoshimasa ^a,b   Takasugi, Azusa ^a   Toshimitsu, Kohta ^a   Yamada, Shoji ^a   Muramatsu, Toshihide ^a   Kimura, Masaki ^a   Sugiyama, Kazuo ^b   Suzuki, Hiromu ^c   Arai, Eri ^d   Ojima, Hidenori ^d   Kanai, Yae ^d   Saito, Hidetsugu ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

miR 122; Fatty liver; Hepatocellular carcinoma; MicroRNA; Non alcoholic steatohepatitis

Indexed keywords

MICRORNA; MIRN122 MICRORNA, HUMAN;

ANIMAL; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DNA METHYLATION; GENE SILENCING; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; MALE; MOLECULAR GENETICS; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA METHYLATION; GENE SILENCING; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED C57BL; MICRORNAS; MOLECULAR SEQUENCE DATA; NON-ALCOHOLIC FATTY LIVER DISEASE; PROMOTER REGIONS, GENETIC;

EID: 84911031215     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12498     Document Type: Article

References (25)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
3. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
4. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-65.
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-31.
7. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-50.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
9. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
10. Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-43.
11. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009; 379: 726-31.
12. Saito Y, Suzuki H, Tsugawa H et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009; 28: 2738-44.
13. Saito Y, Suzuki H, Taya T et al. Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. Biochem Biophys Res Commun 2012; 426: 33-7.
14. Kawai D, Takaki A, Nakatsuka A et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 2012; 56: 912-21.
15. Fujii M, Shibazaki Y, Wakamatsu K et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 2013; 46: 141-52.
16. Sugiishi A, Kimura M, Kamiya R et al. Derangement of ghrelin secretion after long-term high-fat diet feeding in rats. Hepatol Res 2013; 43: 1105-14.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
18. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-81.
19. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-9.
20. Fornari F, Gramantieri L, Giovannini C et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-7.
21. Li ZY, Xi Y, Zhu WN et al. Positive regulation of hepatic miR-122 expression by HNF4alpha. J Hepatol 2011; 55: 602-11.
22. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-94.
23. Hsu SH, Wang B, Kota J et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871-83.
24. Jung CJ, Iyengar S, Blahnik KR et al. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS ONE 2011; 6: e27740.
25. Song K, Han C, Zhang J et al. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology 2013; 58: 1681-92.